Alzheimer’s Research To Be More Collaborative, Better Funded Under National Plan
This article was originally published in The Pink Sheet Daily
Most of the additional money will help support two trials – one for insulin as a treatment and one for crenezumab as a preventative. The Obama administration formally launched its national Alzheimer’s plan in the midst of a two-day meeting that underscored how little researchers know about the disease.
You may also be interested in...
The Swiss biotech raises $22 million in a Series D from its existing private investors to support its research into Alzheimer’s disease therapies.
Alzheimer’s disease science is in disarray and the risk associated with developing disease-modifying agents has driven many players from the field. But venturesome biotechs are finding backers to support efforts to look for a way forward: we profile Alzheon Inc., Neurotrack Inc., Rodin Therapeutics Inc., and Tetra Discovery Partners LLC.
Leading Alzheimer’s experts discuss the status of new therapeutic approaches based on the pathophysiology of related diseases, new gene discoveries from GWAS, the inflammatory cascade and environmental epigenetics. Surprisingly, there is still untapped promise in a-beta and tau.